Evonik Strengthens Its Position in Pharmaceutical Industry

Evonik Strengthens Its Position in Pharmaceutical Industry

Author: ChemistryViews

Evonik Industries formally acquired the entire RESOMER® business of Boehringer Ingelheim Pharma GmbH & Co. KG on March 1, 2011. This acquisition involved transferring the entire product portfolio comprising standard and customer-specific polymers for medical applications and pharmaceutical formulations to Evonik’s Pharma Polymers Business Line. The purchase agreement was signed in December 2010. The companies agreed not to disclose details of the purchase price.

In recent years, Evonik has strengthened its position as a producer of active pharmaceutical substances. In the United States, it took over Eli Lilly’s more than 600-employee-strong Tippecanoe site. A new medical products plant has been built in Nanning, China.


Comments

  1. taylor star

    There is a lot of discussion about the state of medical care in the U.S. The doctor-patient relationship is heavily emphasized, for instance. There is an issue concerning physicians and their prescription practices which has been somewhat muted. Several accuse doctors of accepting pharmaceutical business kickbacks in order to recommend certain medications, and not always to the benefit of the patients. This issue has been ongoing for some time. It is getting to the point that the medical industry as a whole is said to be rife with corruption. The proof is here: Pharmaceutical kickbacks continue to plague medical industry .

    Reply

Leave a Reply

Your email address will not be published.